{"id":"NCT02639247","sponsor":"Gilead Sciences","briefTitle":"Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor","officialTitle":"A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-23","primaryCompletion":"2016-10-05","completion":"2017-01-18","firstPosted":"2015-12-24","resultsPosted":"2017-11-06","lastUpdate":"2019-03-05"},"enrollment":333,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus Infection"],"interventions":[{"type":"DRUG","name":"SOF/VEL/VOX","otherNames":["Vosevi速","GS-7977/GS-5816/GS-9857"]},{"type":"DRUG","name":"SOF/VEL","otherNames":["Epclusa速","GS-7977/GS-5816"]}],"arms":[{"label":"SOF/VEL/VOX","type":"EXPERIMENTAL"},{"label":"SOF/VEL","type":"EXPERIMENTAL"}],"summary":"The primary objectives of the study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (Vosevi速; SOF/VEL/VOX) fixed-dose combination (FDC) for 12 weeks and of sofosbuvir/velpatasvir (Epclusa速; SOF/VEL) FDC for 12 weeks in direct-acting antiviral (DAA)-experienced adults with chronic hepatitis C virus (HCV) infection with or without cirrhosis who have not received prior treatment with a regimen containing an inhibitor of the HCV NS5A protein.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","timeFrame":"Posttreatment Week 12","effectByArm":[{"arm":"SOF/VEL/VOX 12 Weeks","deltaMin":97.8,"sd":null},{"arm":"SOF/VEL 12 Weeks","deltaMin":90.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":78,"countries":["United States","Australia","Canada","France","Germany","New Zealand","Puerto Rico","United Kingdom"]},"refs":{"pmids":["28564569"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":182},"commonTop":["Headache","Fatigue","Diarrhoea","Nausea","Back pain"]}}